Diabetes &
Primary Care

Issue:

Share this article

+ Add to reading list - Remove from my list

PCDS statement: Managing the temporary shortage of NovoRapid FlexPen devices

Hannah Beba

Publisher’s note: This supply shortage has now been resolved and stocks have stabilised. Future orders are expected to arrive in the UK as planned through to the end of the year and beyond.

Advice on switching to alternative devices or insulins during the temporary shortage.

Save, Share, Print Article

Share this article

+ Add to reading list – Remove from reading list

↓ Download pdf

The NovoRapid® FlexPen® will be out of stock until 21 November 2022. It is advised that healthcare professionals DO NOT initiate any new patients on NovoRapid FlexPen during this time. This shortage is likely to be emotive and may result in people accessing healthcare providers for advice during this time. Where possible, allay fears. If someone is already on NovoRapid FlexPen and is concerned that they do not have enough supply to last the next two weeks, then follow the steps below.

Helpful resource

How to calculate the amount of insulin to prescribe per month

Click here to access

Clinical guidance, Devices, Insulins, Workforce issues

Diabetes &
Primary Care

PCDS statement: Managing the temporary shortage of NovoRapid FlexPen devices

Helpful resource

Conference over coffee: New medicines, goals of triple therapy, AI prescribing, hypoglycaemia and lipids

Diabetes Distilled: Cardiovascular autonomic neuropathy – prevention, identification and management

Interactive case study: Managing acute illness in type 2 diabetes

Diabetes Distilled: ABCD–UKKA concise recommendations for management of CKD in type 2 diabetes

Welcome to the new PCDS Chair and Secretary

Conference over coffee: Diabetes and obesity initiatives, multiple long-term condition management and the bookends of pregnancy

Scottish Government and NHS Scotland consensus statement on GLP-1-based therapies for obesity